Related Experiment Videos
Prostate specific antigen in as a dynamic model in advanced prostate cancer
H P Schmid1, J Bernhard, A Semjonow
1Department of Urology, Westfälische Wilhelms-University, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany.
Anticancer Research
|May 1, 2001
Summary
Prostate specific antigen doubling time (PSADT) is a prognostic factor in prostate cancer. This study found PSADT rose exponentially in patients with hormone-resistant prostate cancer receiving chemotherapy, suggesting its potential as a surrogate endpoint.
Area of Science:
- Oncology
- Prostate Cancer Research
- Chemotherapy Efficacy
Background:
- Prostate specific antigen doubling time (PSADT) is an established prognostic factor in prostate cancer treatment.
- The role of PSADT in patients undergoing chemotherapy for prostate cancer remains unevaluated.
Purpose of the Study:
- To evaluate the role of PSADT in patients with hormone-resistant prostate cancer receiving chemotherapy.
- To assess the prognostic value of PSADT in this patient population.
Main Methods:
- A prospective phase II study enrolled 30 patients with hormone-resistant prostate cancer.
- Patients received oral Idarubicin (35 mg on days 1 and 8 every 3 weeks).
- Prostate specific antigen (PSA) levels and PSADT were monitored.
Main Results:
- Of 26 fully evaluable patients, 10 experienced disease progression.
- PSA levels rose exponentially in non-responding patients.
- The median PSADT for patients with rising PSA was 2.1 months.
Conclusions:
- PSA levels increased exponentially in non-responding patients treated with Idarubicin, similar to hormonal therapy.
- PSADT may serve as a surrogate endpoint in hormone-resistant prostate cancer.
- Further evaluation in larger cohorts is warranted.